2016 annual financial data
CRISPR Therapeutics 2016 Net margin
CRISPR Therapeutics 2016 net margin with verified reported values.
Direct answer
Net margin was -449.3%.
Operating income was -68,130,000 USD and net income was -23,202,000 USD.
Operating cash flow was -55,310,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 5,164,000 USD
- Operating income
- -68,130,000 USD
- Net income
- -23,202,000 USD
- Operating cash flow
- -55,310,000 USD